The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Study participants were randomly assigned to receive semaglutide 1mg once weekly (n=1767) or placebo (n=1766) and were followed for a median of 41 months. Efficacy was established based on the ...